Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2020

June 2020 | 1561 pages | ID: BC7B1CDCB9CEN
Global Markets Direct

Abstracts

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer - Pipeline Review, H1 2020, provides an overview of the Bile Duct Cancer (Oncology) pipeline landscape.
Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bile Duct Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 82, 62, 1, 2, 27, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages comprises 6, 4, 2, 1 and 4 molecules, respectively.
Bile Duct Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bile Duct Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bile Duct Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Bile Duct Cancer (Cholangiocarcinoma) - Overview
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbbVie Inc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ability Pharmaceuticals SL, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ABM Therapeutics Inc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Alphamab Oncology, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AltruBio Inc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Andes Biotechnologies, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Apollomics Inc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ascelia Pharma AB, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Ltd, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2020
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
Ability Pharmaceuticals SL
ABM Therapeutics Inc
Advenchen Laboratories LLC
Agios Pharmaceuticals Inc
Alphamab Oncology
AltruBio Inc
Andes Biotechnologies
Apollomics Inc
Ascelia Pharma AB
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Betta Pharmaceuticals Co Ltd
BioMed Valley Discoveries Inc
BJ Bioscience Inc
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Boston Biomedical Inc
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Cellestia Biotech AG
Celltrion Inc
Celon Pharma SA
Chineo Med Beijing Co Ltd
Clovis Oncology Inc
Coherent Biopharma
Convalife
Corcept Therapeutics Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curegenix Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Delcath Systems Inc
Delta-Fly Pharma Inc
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
Elicio Therapeutics
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Forma Therapeutics Inc
Fujifilm Holdings Corp
Genoscience Pharma
GlaxoSmithKline Plc
GO Therapeutics Inc
Gracell Biotechnology Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
H3 Biomedicine Inc
Harbin Gloria Pharmaceuticals Co Ltd
Huabo Biopharm Co Ltd
Hutchison MediPharma Ltd
ImCare Biotech LLC
Immunitor Inc
Incyte Corp
Inmune Bio Inc
InnoCare Pharma Ltd
Innopharmax Inc
Innovent Biologics Inc
Intensity Therapeutics Inc
Ipsen SA
J-Pharma Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kangen Pharmaceuticals Co Ltd
Karus Therapeutics Ltd
Kinnate Biopharma Inc
Komipharm International Co Ltd
Leap Therapeutics Inc
Lexicon Pharmaceuticals Inc
Lokon Pharma AB
Luzitin SA
MacroGenics Inc
Marino Biotechnology Co Ltd
MaxCyte Inc
MediciNova Inc
Medivir AB
Merck & Co Inc
Merck KGaA
Mina Therapeutics Ltd
Molecular Templates Inc
Mundipharma EDO GmbH
Nanjing Transthera Biosciences Co Ltd
NanoCarrier Co Ltd
Newish Technology Beijing Co Ltd
Nkarta Inc
Northwest Biotherapeutics Inc
Novartis AG
NuCana Plc
Oasmia Pharmaceutical AB
Oncocross Co Ltd
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Orgenesis Inc
PCI Biotech Holding ASA
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Provecs Medical GmbH
Puma Biotechnology Inc
Puretech Health Plc
QED Therapeutics Inc
Quadriga BioSciences Inc
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Redx Pharma Plc
RemeGen Ltd
Rgenix Inc
Samyang Holdings Corp
Sanofi
Seald AS
Seattle Genetics Inc
Senhwa Biosciences Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Bioscience Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sillajen Biotherapeutics
Sinocelltech Ltd
Sirnaomics Inc
SMT bio Co Ltd
Sorrento Therapeutics Inc
Sotio AS
Starpharma Holdings Ltd
Sun Pharma Advanced Research Company Ltd
SupremeCure Pharma Inc
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
SyntheX Inc
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
TCR2 Therapeutics Inc
tella Inc
Tempest Therapeutics Inc
Therillia Development Co Inc
Toray Industries Inc
TOT Biopharm Co Ltd
Transcenta Holding Ltd
VasGene Therapeutics Inc
Xencor Inc
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Zymeworks Inc